Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetes--renal function--what are the special problems?

E Ritz1, G Miltenberger-Miltenyi, J Wagner

  • 1Department Internal Medicine, Ruperto Carola University Heidelberg, Germany.

Basic Research in Cardiology
|December 2, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.

Clinical nephrology·1992
Same author

Reduced capillary density in the myocardium of uremic rats--a stereological study.

Kidney international·1992
Same author

Renal histology in polycystic kidney disease with incipient and advanced renal failure.

Kidney international·1992
Same author

The effect of uninephrectomy on progression of renal failure in autosomal dominant polycystic kidney disease.

Journal of the American Society of Nephrology : JASN·1992
Same author

Severe hemorrhagic complications from infection with nephropathia epidemica strain of Hantavirus.

Clinical nephrology·1992
Same author

Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies.

Kidney international. Supplement·1992

Angiotensin-converting enzyme (ACE) inhibitors slow diabetic nephropathy progression, particularly in type 1 diabetes. Angiotensin II receptor blockers also show promise, with ongoing studies to determine long-term efficacy.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a leading cause of end-stage renal failure.
  • The renin-angiotensin system (RAS) plays a critical role in diabetic nephropathy.
  • Intrarenal RAS activity may be elevated despite suppressed circulating RAS components in diabetes.

Purpose of the Study:

  • To review the role of RAS blockade in managing diabetic nephropathy.
  • To evaluate the efficacy of ACE inhibitors and angiotensin II receptor blockers (ARBs).
  • To discuss the impact of these agents on micro-albuminuria and advanced renal failure.

Main Methods:

  • Review of existing literature on RAS blockade in diabetic nephropathy.
  • Analysis of studies involving ACE inhibitors and ARBs in diabetic patients and animals.

Related Experiment Videos

  • Comparison of ACE inhibitors, ARBs, and other antihypertensive agents.

    • Main Results:

    • ACE inhibitors effectively reduce micro-albuminuria in both IDDM and NIDDM.
    • ACE inhibitors slow advanced renal failure progression in IDDM, with preliminary evidence in NIDDM.
    • ARBs show promise in preventing glomerular lesions in diabetic animals and reducing proteinuria in patients.

    Conclusions:

    • RAS blockade, particularly with ACE inhibitors, is crucial for managing diabetic nephropathy.
    • ACE inhibitors demonstrate superiority over conventional agents in specific hypertensive contexts.
    • Further long-term studies are needed to fully elucidate the role of ARBs in advanced diabetic nephropathy.